Journal of Thrombosis and Haemostasis, 21, 499-512 Journal of thrombosis and haemostasis : JTH, 21(3), 499-512. Wiley-Blackwell Publishing Ltd Journal of Thrombosis and Haemostasis, 21, 3, pp. 499-512 Journal of thrombosis and haemostasis : JTH, 21(3), 499-512. Wiley-Blackwell Journal of Thrombosis and Haemostasis, 21(3), 499-512. Wiley
Annals of Hematology, 102(6), 1395-1408. Springer Verlag Annals of Hematology, 102, 6, pp. 1395-1408 Geelen, I G P, Gullaksen, S-E, Ilander, M M, Olssen-Strömberg, U, Mustjoki, S, Richter, J, Blijlevens, N M A, Smit, W M, Gjertsen, B T, Gedde-Dahl, T, Markevärn, B, Koppes, M M A, Westerweel, P E, Hjorth-Hansen, H & Janssen, J J W M 2023, ' Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response : clinical and immunological effects ', Annals of Hematology, vol. 102, no. 6, pp. 1395-1408 . https://doi.org/10.1007/s00277-023-05199-1
Journal of Thrombosis and Haemostasis, 20(4), 833-844. Wiley-Blackwell Publishing Ltd Journal of Thrombosis and Haemostasis, 20(4), 833-844. Wiley Journal of Thrombosis and Haemostasis, 20, 833-844 Journal of Thrombosis and Haemostasis, 20, 4, pp. 833-844